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Summary: During the toxicological examination of the fibrosuppressive agent, Lufironil (INN), in rats a dose-
dependent positive reaction for urinary bilirubin was observed. This positive reaction was found in quantitative
assays, and when using test Strips.
The positive reaction for bilirubin in these assay Systems was caused by a metabolite of Lufironil. It was not due
to drug toxicity, and it was not caused by any endogenous Substrate produced under the influence of Lufironil.
The cömpound responsible for this reaction was isolated by HPLC and its structure determined by spectroscopic
rnethods. The structure was confirmed by syrithesis, starting from pyridine-2,4-dicarboxylate. The synthesized cöm-
pound and the cömpound in urine gave an identical reaction with the test reagent for bilirubin.
Introduction
Reduction of the pathological accumulation of Collagen
in liver by an inhibitor of prolyl 4-hydroxylase1), a key
enzyme of Collagen biosynthesis, offers a new and pro-
mising approach in the treatment of liver fibrosis in man
(1—3). Lufironil (fig. 1) is selectively activated to a
cpmpetitive inhibitor of prolyl 4-hydroxylase in the liver
of rats (4). Lufironil is rapidly and eompletely absorbed
after oral administration in rats and dogs. About 75% of
the cömpound äiid its metabolites are excreted in the
urine (5). Studies in humans were initiated in 1990 (6).
During the toxicological examination of Lufironil, a
highly positive reaction for bilirubin was observed in
CO- NH- CH2- CHfc- O - CH3
CO NH- CH?- CH2- O - CH3
Fig. l Chemical structure of Lufironil (INN), pyridine-2,4-diear-
boxylic acid bis^ ((2-methoxyethyl)-arnide), [Company code
nuraber: HOB 077].
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urine samples of rats using qualitative urinalysis tests,
although the serum values remained in the normal ränge.
Drug interference in clinical laboratory tests are well
known, and a number of compounds have been pub-
lished which interfere with bilirubin assay Systems
(7-10).
The aim of the study was to clarify whether the positive
results obtained with the bilirubin assay Systems in urine
were caused by a toxic effect of Lufironil, or by a
chemical reaction of a metabolite of Lufironil with the
bilifubin test reagent.
Materials and Methods
Measurement of urinary bilirubin in a toxicity study in
rats after repeated administrations of Lufironil
Lufironil was given to groups of 10 male and 10 female Wistar
rats (110 g body weight) in doses of 100, 500 and 2500 mg/kg on
30 consecutive days. The drug was dissolved in deionized water
!) Enzymes: Bilirubin oxidase EC 1.3.3.5, Prolyl 4-hydroxylase
EC 1.14.11.2.
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and administered orally in a volume of 5 ml/kg. Two groups,
n = 10 each, of age and sex-matched rats served äs controls. The
animals vvere kept under Standard conditions, with a night/day
rhythm from 6 p. m. to 6 a. m., at 22 °C room temperature, and fed
Standard peilets Altromin™ 1234 (Altromin GmbH, Lage/Lippe,
Germany) and water ad libitum.
During the last week of the study the animals were placed in meta-
bolic cages for urine collection overnight (approximately 16
hours). The concentration of bilirubin in these urine samples was
measured, using qualitative and quantitative bilirubin assays
(11-13).
On the day of necropsy, before the animals were sacrificed, blood
was withdrawn from the conscious, non-fasted animals for analysis
of the blood cell count and determination of serum values.
Investigations of serum values and macroscopical and histological
examinations were performed according to Donaubauer & Mayer
(14).
Measurement of bil irubin in the urine of female rats
after a single administration of Lufironil
Female Sprague Dawley rats (300 ± 30 g body weight) received
a single dose of 1000 mg/kg Lufironil (n = 8). The compound was
dissolved in saline and administered orally in a volume of 2 ml/
kg. Control rats received the saline alone (n = 7). Fifteen minutes
later the animals were anaesthetized by intramuscular injectipn of
urethane (l .5 g/kg body weight). 60 minutes after the i. m. injection
the animals were laparotomized and the urinary bladder drained.
Saline was infused via the jugular vein with a flow rate of 6 ml/h
per rat to induce diuresis, in order to obtain sufficient amounts of
urine for analysis. Urine samples were collected at 30 minute inter-
vals for a total period of 10 hours, the volume of the samples was
noted and the bilirubin concentration in the urine was measured
using the method of Jendrassik & Gro/(13).
Bil i rubin test Strips and tablets
Rapignost Total-Screen, Behringwerke AG, Marburg, Germany
Ictotest, Ames, Bayer Diagnostic, München, Germany
Determination of total and conjugated bilirubin
Jendrassik-Grof, Merck, Darmstadt, Germany, cat. No. 3333
DPD-Method, BMC, Mannheim, Germany, cat. No. 123943
Enzymatic bi l i rubin test
Bilirubin oxidase1) assay, Sigma, St. Louis, USA, cat. No. B 0390
High-Performance Liquid Chromatography (HPLC)
HPLC: Spectra Physics, Darmstadt, Germany; Pump SP 8800,
Auto sampler SP 8780, Integrator SP 4270, UV-Detector SP 8490.
Detection wavelength: 578 nm
Column: Nucleosil 120-5 C18 ET 125/8/4, Macherey + Nagel,
Düren, Germany.
Gradient elution: Eluent A = 0.05 mol/1 phosphoric acid + 20 ml/l
Eluent B = acetonitrile, 5 min 100% A, 20 min 90% A, 25 min
60% A, 30 min 60% A, 35 min 100% A
Flow rate: 1.2 ml/min.
Spectroscopic measufements
UV spectra: Perkin-Elmer 554, Überlingen, Germany
NMR spectra: Bruker AM-270, Karlsruhe, Germany
Mass spectra: VG Analytical ZAB-2SEQ, Manchester, United
Kingdom, equipped with a caesium ion gun operated at 30 kV;
FAB matrix 3-nitro-benzylalcohol, polyethylene glycol-400 used
äs internal reference for high-resolution mass measurement.
Radiochemical determination
Female Wistar rats (250-260 g body weight) received a single
dose of 1000 mg/kg Lufironil (n = ji). The compound was dis-
solved in saline and administered orally in a volume of 4rnl/kg.
Three hours later, these same animails received a second oral dose
of 1000 mg/kg I4C-labelled Lufironil, (2-carbamoyl-14C), <5).
Thereafter the animals were placed in metabolic cages and urine
was collected for 24 hours; the urine from all rats was pooled (Ul).
An aliquot (l ml) of Ül was added to the 10 ml dichlorophenyldia-
zonium (DPD) reagent (15, 16). The subsequent Separation by
HPLC of the methanolic solution of this reaction product was per-
formed at 578 nm, and radioactivity was detected, using the föllow·?
ing equipment and conditions:
HPLC: series 8800, Dupont, Wilrnington, United Kingdom;
Photometer with variable wavelength: SF 770, Applied Biosystems
GmbH, Weiterstädt, Germany;
Absorption wavelength: 578 nm;
Radioactivity detector: LB 5026, Berthold, Wildbad, Germany;
Stationary phase: LiChrospher RP-18 (5 ), 250 mm X 4mm,
Bischoff, Leonberg, Germany;
Mobile phase: eluent A: 0.01 mol/1 phosphoric acid, eluent B 10
min 37% A-0% A, 10 min 0%-100% A;
Flow rate: 1.5 ml/min at 25 °C.
Statistical methods
For detection of significant differences, the unpaired t-test was
used. In cases of non-homogeneity of varianceSj the non-parametric
U-test, according to Mann-Whitney was used. Dose response re-
lationships were calculated by linear regression analysis (17).
Results
Bilirubin in urine in the toxieity study in rats
after repeated ädministrations of Lufironil
During the toxicological examination of Lufironil in
rats, a positive reaction for urinary bilirubin was ob-
served when urine was analysed accordirig to Rapignost
and Ictotest (11, 12). To quantify the results, the urine
samples were analysed using the bilirubin assay accord-
ing to Jendrassik & Grof(l3).
Bilirubin concentrations in urine from male and female
rats increased dramatically, and were significantly
(r = 0.933,p < 0.001,malesandr = 0.896,p < 0.001 in
females) correlated with the doses of Lufironil applied.
The increase of bilirubin in urine was slightly more pro-
nounced in female rats than in male rats (tab. 1).
In serum however, there was no difference in bilirubin
levels between cqntrol and drug-treated rats of either
sex. Identical values were obtained for control and drug-
treated animals when serum was analysed with the bili-
rubin oxidase assay (18) or the colorimetric method of
Jendrassik & Grof(l3). In the analysis of urine, how-
ever, the enzymätic assay detected no bilirubin in urine
in either group, whereas the colorimetric method gave a
positive response for bilirubin in the treatment group
(data not shown). r *
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Tab. l Bilirubin in urine in the toxicity study in male and female
















































Results are means ± SD
** p < 0.01 vs. control
a: Total daily dose given orally
These findings indicated that the positive bilirubin reac-
tion obtained using the colorimetric method was prob-
ably not caused by bilirubin in the urine.
Bil i rubin in the urine of rats after a single
administrat ion of Lufironil
Lufironil given s a single dose of 1000 mg/kg to rats
caused a slight diuretic effect, which had also been ob-
served in the preceding toxicity study.
As seen in the toxicity study, the urine of treated animals
showed a tremendous increase of a positive bilirubin re-
action, with values 26-times higher than those recorded
for control animals (tab. 2).
The appearance of this positive bilirubin reaction,
henceforth referred to s the "bilirubin-like reactivity",
started 2 hours after administration of Lufironil and rose
to a maximal value of 37 nmol/0.5 h within l hour. The
bilirubin-like reactivity plateaued for 4 hours, than de-
clined slowly over the next 3 hours (flg. 2).
Isolat ion of the coupling compound (IV)
To obtain the compound responsible for the bilirubin-
like reactivity, a large amount of rat urine was needed.
Urine samples from female Sprague Dawley rats, treated
orally with a daily dose of 2500 mg/kg Lufironil over a
period of 6 months, were pooled and stored frozen.
Since the diazo coupling compound of sulphanilic acid
is insoluble, and therefore unsuitable for HPLC Separa-
tion, the DPD-method, using 2,5-dichlorobenzene s re-
agent (15, 16) was chosen.
To 5 ml portions of urine, 2 ml diazonium sah (DPD-
method) dissolved in 0.1 mol/1 hydrochloric acid were
added. The coupling product was extracted into 4 ml
dichloromethane.
For the first purification step, a Bond Elut silica cohimn
(pre-treated with 2ml dichloromethane) was loaded
with the extract.
The column was washed 4 times with 2 ml dichlorome-
thane, then the compound was eluted with 0.5 ml of a
mixture of dichloromethane and methanol (7 H- l, by
vol.). After evaporation to dryness, the residue was dis-
solved in 100 μΐ methanol and separated by HPLC. The
isolated compound had a retention time of 24 minutes.
Identification of the coupling compound (IV)
The isolated compound had a deep blue colour (Xmax
593 nm, ε 2000 m2/mol) in dichloromethane, whereas it
had a red violet colour (Xmax 543 nm) in methanol, indi-
Tab. 2 Urine secretipn and bilirubin in urine after administration




























Results are means ± SD
* p < 0.05
** p < 0.01 vs. control
a: Average Output calculated from the whole observation period
(10 fa)
b: Total output calculated frorn the whole observation period
(10h)
c: Average Output from 2.5—10 b after application of a single oral
dose of 1000 mg/kg Lufironil
4 6
Time after application [h]
10
Fig. 2 Time-dependent appearance of the bilirubin-like reactivity
in the urine of female rats. Results are means ± SD. Ciosed circles
·-· represent the rats given a single oral dose of 1000 mg/kg
Lufironil (n = 8), closed triangles A-A represent the control group
given saline alone (n = 7).
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cating the presence of a charged chromophoric System.
High-resolution FAß mass spectrometry gave a molecu-
lar formula of CnH^C^NsOs (M + H+ foünd m/z
408.0629, calculated 408.0630). The NMR spectrum
displayed signals for one 2,5-dichloro-phenylazo group,
one pyridine-2,4-dicarboxamide moiety, and one me-
thoxyethylamine group (tab. 3). From these data the
structural formula (IV) for the red dye was deduced. It
was concluded that an azo-coupling product of the
(possibly unstable) cyclic zwitterion (III) could have
been formed under the acidic coupling conditions from
the hydroxymethylene amide (II), a hitherto unknown
metabolite of Lufironil (fig. 3).
Synthesis of the metabolite (II)
The metabolite (II) was synthesized by treatment
of pyridine-4-carboxy-(2-methoxyethyl)-amide-2-carb-
oxamide (V) (synthesized according to Baader (19))
with 35% formaldehyde and potassium carbonate in
water at room temperature for 20 hours (fig. 3).
The product was extracted with dichloromethane. The
organic solvent was sepäfated jfrom the aqueous layer,
dried with sodiürn carbonate and concentrated.
Pyridine-4-carboxy-(2-methoxy-ethyl)-amide-2-cafboxy-
(hydroxy-methyl)-amide (II), was obtained äs a colour-
less solid (mp. 94 °C). This compound, when treated in
aqueous solution with the bilifubm test reagent, gave
the same colour reaction äs that observed with the urine
samples. The pfoduct was also spectroscopically ident-
ical with the red dye (UV, MS, NMR) after HPLC puri-
fication.
Radiochemical analysis
That the false positive bilirübin reaction in urine was
caused by a metabolite of Lufironil was further con-
firmed by radiochemical methods.
Investigation öf the pooled urine (Ul) from rats given a
single dose of 1000 mg/kg unlabelled Lufironil and se-
cond a single dose of 1000 mg/kg of 14C-labelled Lufi-
ronil reveäled that 63% of the administered dose was
excreted in the urine.
When the diazoniurn salt (according to the DPD-method
(15, 16)) was added to the urine, a deep blue-coloured
reaction product was formed following the addition of
dichloromethane.








Fig 3 Sequence of preparation of the coupling compoünd (IV), steps I to IV. Sequence of synthesis -
of the metabolite (II), steps V to II. .;
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After extraction of the processed urine with dichlorome-
thane, most of the radioactivity detected by HPLC was
found to be present in Lufironil and its known metab-
olites. Only approximately 1% of the extracted radioac-
tivity appeared on the chromatogram, with a retention
time of 47.8 minutes. This peak coincided exactly with
the absorption peak of the compound formed by reaction
of the putative Lufironil metabolite (II) with the biliru-
bin reagent used in the DPD-method. From the amount
of radioactivity administered and the quantities of the
metabolite (II) found by HPLC, it is calculated that this
metabolite accounts for less than 0.1% of the amount of
Lufironil given to the animals. Thus it is unlikely that
this metabolite would have been detected, if the unusual
interference with the conventional bilirubin assay sys-
tem had not occurred.
Discussion
Total bilirubin in serum of healthy male and female
Sprague Dawley rats ranges between 1.09-6.45 /1
(20). No bilirubin is present in the urine. The very small
amounts of diazo-positive reaction products in urine
samples (tab. 2) originale from other dipyrrole-contain-
ing structures äs urobilinogen and uroporphyrin.
When bilirubin in serum exceeds concentrations of about
15 /l, however, it is excreted through the kidney
and appears in the urine, where it can be detected by
commercially available bilirubin assay Systems.
An increase of bilirubin in serum, and consequently
urine, generally reflects an imbalance between bilirubin
production, for which the predominant source is haemo-
globin degradation (21), and bilirubin excretion by hepa-
tocytes into the bile. Various conditions are known to
generate such an imbalance: overproduction of bilirubin
under haemolytic conditions, intra- or extra-hepatic ob-
struction of the biliary System, or a decreased capacity
of hepatic bilirubin uptake combined with decreased ca-
pacity of the hepatoeytes tQ conjügate and/or secrete the
conjugated product into the bile (22). The latter con-
dition is usually the conseqüence of hepatocellular dam-
age or death, caused by infectious agents or indüced by
drugs, toxic to the liver.
Haemätolögical values obtained in the toxicity study of
Lufironil did not give any signs of a haemolytic process,
leading to overproduction of bilirubin. Haemoglobin and
red cell and reticulocyte counts were within their nor-
mal ranges.
Histological examination of the rat livers and the biliary
tract of the rats in the toxicity study excluded an intra- or
extra-hepatic obstructive process of the biliary draining
System (24).
Competition of Lufironil and/or its metabolites with
hepatic bilirubin uptake, which is known to occur with
the antibiotic rifampicin (23), was unlikely, because this
would have led to an elevation of serum bilirubin, which
was not found.
A toxic effect of Lufironil on the hepatoeytes was ex-
cluded by the histological examination of the rat livers
from the toxicity study; no abnormalities of the hepato-
eytes were detected.
In addition, serum levels of the liver enzyme, aspartate
aminotransferase, and of bilirubin were in the normal
ränge, while alkaline phosphatase was decreased rather
than increased (24).
The finding of normal bilirubin serum levels excluded a
true elevation of bilirubin in urine and led us to suspect
a false positive bilirubin reaction.
False positive bilirubin reactions using diazo-reagents
have been reported after the administration of several
drugs: sulphonamides (7), the analgesic flupirtine (8),
indican (9) and methotrexate (10).
Therefore we focused our investigations on the possibil-
ity that the bilirubift-like reactivity in the urine of rats
might have been caused by an unknown metabolite of
Lufironil reacting with the diazo reagent of the bilirubin
assay Systems. We showed that the bilirubin-like reacti-
vity found in rat urine following high doses of Lufironil
was a reaction product of a very minor metabolite (II)
of Lufironil (fig. 3) with the diazo-reagent.
This finding was of practical importance for ongoing
human studies, in the event that bilirubin-like reactivity
would be detectable in human urine.
However, elevated urinary bilirubin reactions have not
yet been observed in healthy volunteers given Lufironil
at doses up to 2400 mg/kg per day (6).
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